BELLEVILLE, ON, Oct. 4 /CNW/ - Bioniche Life Sciences Inc. (TSX: BNC), a
research-based, technology-driven Canadian biopharmaceutical company,
announced that Cameron Groome, Executive Vice-President, Corporate & Strategic
Development will present today at BioContact Quebec 2007, an annual
biopharmaceutical partnership symposium being held in Quebec City this week.
Mr. Groome will present at 10:00 a.m. (Eastern) in Salle Frontenac.
More than 150 biopharmaceutical companies are attending BioContact
Quebec, from Canada, the United States, Asia and Europe. Companies represent
diagnostics, therapeutics and services, covering such disciplines as Cancer,
Cardiology, Genomics/Proteomics, Immunology/Infectiology and more.
The forum provides an opportunity to update peers in the
biopharmaceutical industry about recent accomplishments of Bioniche, including
the agreement with the U.S. Food & Drug Administration on a Special Protocol
Assessment (SPA) for the Company's second Phase III pivotal clinical trial in
first-line bladder cancer patients; the progress being made in the first Phase
III clinical trial in refractory bladder cancer patients; the first commercial
sales of its E. coli O157:H7 vaccine for cattle; and the vaccine's recognition
as the best new veterinary product for livestock globally.
About Bioniche Life Sciences Inc.
Bioniche Life Sciences Inc. is a research-based, technology-driven
Canadian biopharmaceutical company focused on the discovery, development,
manufacturing, and marketing of proprietary products for human and animal
health markets worldwide. The fully-integrated company employs approximately
195 skilled personnel and has three operating divisions: Human Health, Animal
Health, and Food Safety. The Company's primary goal is to develop proprietary
cancer therapies supported by revenues from marketed products in human and
animal health. For more information, please visit www.Bioniche.com.
Except for historical information, this news release may contain
forward-looking statements that reflect the Company's current expectation
regarding future events. These forward-looking statements involve risk and
uncertainties, which may cause, but are not limited to, changing market
conditions, the successful and timely completion of clinical studies, the
establishment of corporate alliances, the impact of competitive products and
pricing, new product development, uncertainties related to the regulatory
approval process, and other risks detailed from time to time in the Company's
ongoing quarterly and annual reporting.
For further information:
For further information: Jennifer Shea, Corporate Communications &
Investor Relations Manager, Bioniche Life Sciences Inc., Telephone: (613)
966-8058, Cell: (613) 391-2097, Jennifer.Shea@Bioniche.com